CEA and CA 15-3 in breast cancer: Their importance in diagnosing primary tumours, local recurrences and distant metastases;CEA and CA 15-3 beim Mammakarzinom: Ihre Bedeutung fur die Diagnose von Primartumoren, Lokalrezidiven und Fernmetastasen

Geburtshilfe und Frauenheilkunde

Volumn 56, Issue 11, 1996, Pages 618-624

  Kramer S ^a,b   Jager W ^a   Wildt, L ^a   Lang, N ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS;

EID: 0029854199     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023295     Document Type: Article

References (22)

1. Colomer, R., A. Ruibal, L. Salvador: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64 (1989) 1674-1681.
2. Crombach, C., H. Würz. W. Antczak, K. Reusch, F. Hermann, A. Bolte: Wertigkeit des tumorassoziierten Antigens CA 15-3 beim Mammakarzinom. In Greten, H., R. Klapdor (Hrsg.): 3. Ham-burger Symposium über Tumormarker. Thieme, Stuttgart (1986) 184-194.
3. van Dalen, A., J. M. G. Bonfrer, H. W. Dupree, K. J. Heering, D. L. van der Linde, W. J. Nooijen: CA 15-3 pre-operatively and during the follow-up of breast carcinoma patients. 3. Hamburger Symposium über Tumormarker, Hrsg.: H. Greten, R. Klapdor. Thieme, Stuttgart ( 1986) 227-233.
4. Engel, K., H. Schmid. J. Hanke, M. Kaufmann, A. Müller: CA 15-3 und CEA als Tumormarker zur Rezidivdiagnostik beim Mammakarzinom. Geburtsh. u. Frauenheilk. 48 (1988) 309-312.
5. Eskelinen, M., S. Tikanoja, Y. Collan: Efficient Test for Cancer Antigens: Decreased Levels of Cancer Antigen in Serum After Excision of Breast Tumor. Anticancer Res. 9 (1989) 437-440.
6. Gion, M., R. Mione, O. Nascimben, M. Valsecchi, C. Gatti, A. Leon, G. Bruscagnin: The tumour associated antigen CA 15-3 in primary breast cancer. Evaluation of 667 cases. Br. J. Cancer 63 (1991) 809-913.
7. Gold, P., S. O. Freedman: Demonstration of tumor-specific antigens in human carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 121 (1965) 439-462.
8. Hayes, D. F., V. R. Zurawski, D. Kufe: Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J. Clin. Oncol. 4 (1986) 1542-1550.
9. Hölzel, W. G. E., R. Beer, W. Deschner, A. Griesmacher, M. M. Müller: Individual reference ranges of CA 15-3, MCA and CEA in recurrence of breast cancer. Scand. J. Clin. Lab. Invest. 55 (1995) 93-101.
10. Jäger, W., W. Sauerbrei, M. Diedrich, R. Krempel, L. Wildt: CA 15-3-Serumkonzentrationen während 24h bei Patientinnen mit primärem und metastasiertem Mammakarzinom. Onkologie 10 (1987) 290-293.
11. Jäger, W., E. Merkle, A. H. Tulusan, N. Lang: Modifizierte Mammakarzinom-Nachsorge. Gynäkol. Rundsch. 31, Suppl. 2 (1991) 296-299.
12. Jäger, W.: The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Europ. J. Cancer Prevent. 2, Suppl. 3 (1993) 133-139.
13. Jäger, W., S. Krämer, V. Palapelas, N. Lang: Breast cancer and clinical utility of CA 15-3 and CEA. Scand. J. Clin. Lab. Invest. 55 (1995) 87-92.
14. Burtin, P., S. v. Kleist: Auto-anticorps chez les cancéreux. Presse-Med. 73 (1965) 2599-2603.
15. Krämer, S., G. Reinhardt, W. Jäger: Is there still a relevance for measuring CEA during follow-up in breast cancer patients? In Klapdor, R. (ed.): Current Tumor Diagnosis. W. Zuckschwerdt Verlag, (1994).
16. Kreienberg, R., V. Möbus: Erste Erfahrungen mit einem neuen Tumormarker (CA 15-3) bei Mammakarzinomen. 3. Hamburger Symposium über Tumormarker. Hrsg.: Greten, H., R. Klapdor. Thieme, Stuttgart (1986).
17. Lamerz, R., P. Stieber, A. Fateh-Maghadam: Serum Marker Combinations in Human Breast Cancer. In vivo 7 (1993) 607-614.
18. Molina, R., G. Zanon, X. Filella, F. Moreno, J. Jo, M. Daniels, M. Latre, N. Gemenez, J. Pahisa, M. Velasco, A. Ballesta: Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients. Breast Cancer Res. Treat. 11 (1995).
19. Pons-Anicet, D. M. F., B. P. Krebs, R. Mira, M. Namer: Value of CA 15-3 in the follow-up of breast cancer patients. Brit. J. Cancer 55 (1987) 567-569.
20. Safi, F., I. Kohler, E. Röttinger, H. G. Beger: The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. Cancer 68 (1991) 574-582.
21. Schmidt-Rhode, P., C. Sturm, K.-D. Schulz, T. Bauer, M. Frick: Erste Erfahrungen mit einem neuen Tumormarker (CA 15-3) beim Mammakarzinom. 3. Hamburger Symposium über Tumormarker, Hrsg.: Greten, H. u. R. Klapdor. Thieme, Stuttgart (1986) 159-173.
22. Tobias, R., C. Rothwell, J. Wagner, A. Green, Y. S. Liu: Development and evaluation of radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115 D8/DF-3. Clin. Chem. 31 (1985) 986.